FMFergal J. Moloney

Fergal J. Moloney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fergal J. Moloney has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Malignant melanoma in transplant patients: review of five cases

    by M. E. Laing, F. J. Moloney, E. W. Kay, P. Conlon, G. M. Murphy

    The characteristics of malignant melanoma arising in transplant patients are not clearly delineated. We describe clinical and histological features of malignant melanoma in five transplant patients. All transplant patients with melanoma arising post-transplantation had a previous history of skin cancer. Two had a history of internal organ malignancy. Three patients had thick malignant melanomas (Clark level III or higher, or >0.76 mm Breslow thickness). Lymph-node metastases occurred in one patient with cutaneous melanoma. Local cutaneous metastases occurred in one patient. Mean duration from transplantation to melanoma was 15.6 years. Two cases of aggressive metastatic melanoma responded well to cessation of immunosuppression. Three patients with nonmetastatic disease responded well to conventional complete excision and continuation of immunosuppression.


  • ? Iatrogenic phytophotodermatitis resulting from herbal treatment of an allergic contact dermatitis.

    by F. J. Moloney, J. Parnell, C. C. Buckley

    Phytophotodermatitis commonly occurs in skin exposed to sunlight after contact with plants containing furocoumarins. While it is recognized that the consumption of plants or vegetables containing furocoumarins can potentially trigger a phytophotodermatitis, there have been no reports to date of a phytophotodermatitis triggered by an ingested herbal remedy. We describe the case of a 56-year-old farmer who developed an extensive photo-induced dermatitis after ingesting a herbal decoction prescribed for his chronic hand dermatitis.


  • The impact of skin disease following renal transplantation on quality of life

    by F.J. Moloney, S. Keane, P. O'Kelly, P.J. Conlon, G.M. Murphy

    Background The immunosuppressive therapy a patient requires to sustain a functioning renal allograft in the long term is associated with various skin complications. While quality of life (QoL) after renal transplantation has been studied, no publications document the effect of post-transplant dermatological complications on QoL. Objectives The objective of the study was to document the prevalence of the skin diseases that commonly occur in association with post-transplant immunosuppression. A general dermatological quality of life questionnaire, the Dermatology Life Quality Index (DLQI), was used to assess the QoL effect of these cutaneous complications. The study was designed to examine further the impact of age, sex, duration since transplant and immunosuppressive regimen on the DLQI score of renal transplant recipients (RTR). Methods One hundred and seventy-three RTR completed the DLQI, were interviewed and examined for evidence of common post-transplant skin diseases. Results Sixteen per cent of RTR had DLQI scores >6, reflecting a significant impact on their QoL. Dry skin, itch, hypertrichosis, sebaceous gland hyperplasia, acne, genital warts and a history of >4 herpes simplex virus type 1 infections in the past year were all found to have a significant impact on the quality of life (P < 0·05). Multivariate analysis revealed that the greatest impact on QoL was in RTR who were younger, female and with multiple skin problems (P < 0·05). Conclusions The dermatological complications of immunosuppressive therapy are common in RTR and can significantly impair QoL in certain individuals. Visible, infectious and cosmetic skin problems had most impact on QoL while a history of skin cancer had a lesser impact. Early dermatological referral and careful choice of immunosuppression may enhance the QoL, particularly in young and female RTR.


  • Open Access

    Sunscreen Use Before and After Transplantation and Assessment of Risk Factors Associated With Skin Cancer Development in Renal Transplant Recipients

    by Fergal J. Moloney, Esmaeel Almarzouqi, Patrick O’kelly, Peter Conlon, Gillian M. Murphy

    Renal transplant recipients develop neoplasms more commonly compared with the general population, especially squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skin.1 The risk of skin cancer increases in proportion to the duration of immunosuppressive drug use.2 The past decade has seen an exponential increase in the numbers of skin cancers, paralleling the noticeable improvement in long-term graft survival.3 Cumulative sun exposure is also a major contributing risk factor. Of Irish renal transplant recipients, 40% will develop skin cancer after 20 years since transplantation.4 In contrast, over a similar period, 82% of transplant patients in Queensland, Australia, have developed a skin cancer.5 Historically, skin cancer prevention had low priority in the pretransplantation and early posttransplantation period. Seukeran et al6 have previously highlighted poor compliance among transplant recipients with advised sun protection measures. The present study aimed to establish patterns of sunscreen use in the pretransplantation and posttransplantation settings, identify factors associated with poor compliance with sun protection measures, and outline a set of guidelines for skin cancer education and prevention in renal transplant recipients.


  • Renal transplantation, immunosuppression and the skin: an update

    by F. J. Moloney, D. De Freitas, P. J. Conlon, G. M. Murphy

    Transplant medicine has seen many innovations over past decades and continues to evolve into the 21st century. Newer immunosuppressive strategies in renal transplantation are associated with better patient and graft survival rates; however, the adverse toxicities and long‐term side effects associated with these agents present a number of challenges. Certain immunosuppressants are commonly used in dermatologic disorders, however, dermatologists may be less familiar with the clinical efficacy, side‐effect profile, and dosage of newer immunosuppressive agents. A knowledge of the molecular and cellular mechanisms of action of these agents gives us a better understanding of how these agents contribute to the cutaneous and mucosal complications frequently seen post‐transplant. With the advent of new immunosuppressive therapies and different treatment regimens, there is an increasing need for a multidisciplinary approach to balancing the risks and benefits of these medications to the individual transplant recipient. This review will highlight the different immunosuppressive agents and their effect on the skin while focusing on the evidence base to support the commonly used immunosuppressive regimes, newer protocols aimed at achieving maximum graft survival with minimal side effects, and important drug interactions with which all dermatologists should be familiar.